tbuckley/cabot-search huggingface dataset:
Abstract 5390: Chemical disruption of Wnt protein fatty acylation as an anti-cancer therapeutic strategy.
Authors: Rubina Tuladhar, Lawrence Lum
Journal: Cancer Research (2013)

Abstract The secreted Wnt signaling molecules are associated with a broad range of cancers and represent high priority therapeutic targets. Recently identified small molecules that disrupt Wnt biosynthesis by disabling the extracellular acyltransferase Porcupine (Porcn) form the basis of a novel targeted anti-cancer therapeutic strategy. Porcn is a founding member of a sixteen gene family known as Membrane-Bound O-Acyltransferases (MBOATs) that likely control the production of a broad range of disease-relevant signaling molecules. A deeper understanding of the chemical-protein interaction that confers Porcn inhibitors with selectivity would facilitate the engineering of improved Porcn inhibitors and molecules with activity against other MBOAT family members. Using synthetic fatty acyl analogues that allow direct labeling of Wnt proteins and chemical inhibitors of fatty acid metabolic enzymes, we have uncovered that Porcn utilizes a monounsaturated 16-carbon fatty acid as a substrate. Chemical disruption of stearoyl-CoA desturase (SCD) that converts palmitate to palmitoleate blocks Wnt protein production and activity thus revealing another potential chemical strategy for inhibiting Wnt-dependent cancerous growth. The inability of several other Porcn family members with known protein substrates to utilize palmitoleate may account for the selectivity of Porcn classes of inhibitors. Our study expands the number of drug targets to include those enzymes that control the production of secreted signaling molecules and reveals a direct influence of cellular metabolic status on coordinated and cancerous cell growth regulation. Citation Format: Rubina Tuladhar, Lawrence Lum. Chemical disruption of Wnt protein fatty acylation as an anti-cancer therapeutic strategy. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5390. doi:10.1158/1538-7445.AM2013-5390
871 REAL-WORLD EFFICACY AND SAFETY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY
Authors: S. Mauss, K.H.W. Boeker, C. Eisenbach, B. Moeller, G. Moog, T. Lutz, U. Naumann, S. Christensen, M.-C. Jung, G. Teuber, M. Frank Doss, M. Schuchmann, E. Schott, U. Alshuth, D. Hueppe
Journal: Journal of Hepatology (2013)
Potential limitations of the functional movement screen: a clinical commentary
Authors: Alexis A Wright, Ben Stern, Eric J Hegedus, Daniel T Tarara, Jeffrey B Taylor, Steven L Dischiavi
Journal: British Journal of Sports Medicine (2016)

Athletic injury and its sequelae remain a primary concern of sports professionals globally. As a result, screening athletes to predict injury is of great interest, especially if the screening/testing procedure is non-invasive, effective, and efficient. One such procedure of increasing popularity is the functional movement screen (FMS), which, in 2007, was reported to predict injury in American football players in a single season.1

The FMS attempts to identify fundamental movement patterns that simultaneously measure range of motion, stability, and balance1 and shows moderate evidence for acceptable reliability when deriving a composite score.2 The FMS attempts to take a comprehensive approach to assess human movement and encourages clinicians to look beyond impairments and isolated single joint motion and explore more comprehensive movement patterns representative of those used in daily activities and sport. Considering the growing popularity of the FMS both clinically and in research literature, its merits warrant closer analysis.

A composite score of ≤14 on the FMS is commonly …
LONG-TERM PROGNOSTIC VALUE OF CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY FINDINGS FOR ASYMPTOMATIC INDIVIDUALS: A 6-YEAR FOLLOW-UP OF 1,226 ASYMPTOMATIC INDIVIDUALS FROM THE PROSPECTIVE MULTICENTER INTERNATIONAL CONFIRM STUDY
Authors: Iksung Cho, Adam Berger, Bríain ó Hartaigh, Stephan Achenbach, Daniel Berman, Matthew Budoff, Tracy Callister, Mouaz Al-Mallah, Filippo Cademartiri, Kavitha Chinnaiyan, Augustin DeLago, Todd Villines, Martin Hadamitzky, Joerg Hausleiter, Jonathon Leipsic, Leslee Shaw, Philipp Kaufmann, Ricardo Cury, Gundrun Feuchtner, Yong-Jin Kim, Erica Maffei, Gilbert Raff, Gianluca Pontone, Daniele Andreini, James Min
Journal: Journal of the American College of Cardiology (2015)
Rising Incidence of Hepatocellular Carcinoma in the United States
Authors: Hashem B. El-Serag, Andrew C. Mason
Journal: New England Journal of Medicine (1999)

Clinical observations have suggested that the number of cases of hepatocellular carcinoma has increased in the United States. We analyzed data from the Surveillance, Epidemiology, and End Results (SEER) data base to determine the age-adjusted incidence of hepatocellular carcinoma from 1976 to 1995, data from the U.S. vital-statistics data base to determine age-adjusted mortality rates from 1981 to 1995, and data from the Department of Veterans Affairs to determine age-adjusted rates of hospitalization for the disease from 1983 to 1997.The incidence of histologically proved hepatocellular carcinoma increased from 1.4 per 100,000 population (95 percent confidence interval, 1.3 to 1.4) for the period from 1976 to 1980 to 2.4 per 100,000 (95 percent confidence interval, 2.3 to 2.4) for the period from 1991 to 1995. Among black men, the incidence was 6.1 per 100,000 for the period from 1991 to 1995, and among white men, it was 2.8 per 100,000. There was a 41 percent increase in the mortality rate from primary liver cancer and a 46 percent increase in the proportion of hospitalizations attributable to this disease during the periods studied. The incidence increased significantly among younger persons (40 to 60 years old) during the period from 1991 to 1995 as compared with earlier periods.An increase in the number of cases of hepatocellular carcinoma has occurred in the United States over the past two decades. The age-specific incidence of this cancer has progressively shifted toward younger people.
Abstract 1338: Chemokine (CXC motif) Ligand 5 protein expression in pancreatic tumors: Exploring chemostatic gradients in the tumor microenvironment
Authors: Carolyn V. Ustach, Clifford J. Whatcott, Christopher Kingsley, Galen Hostetter, Michael Barret, Manuel Hidalgo, Caroline H. Diep, Aprill Watanabe, Michael Demeure, Haiyong Han, Daniel D. Von Hoff
Journal: Cancer Research (2010)

Abstract Due to lack of early presenting symptoms, pancreatic cancer is often diagnosed late when the tumor is highly invasive with aggressive clinical course and conventional therapies are limited in their effectiveness. Identifying molecular targets which contribute to tumor aggressiveness and metastasis could lead to development of better therapies to treat pancreas cancer patients. To identify potential molecular targets, we applied a specialized bioinformatics Breakpoint/Gene Aberration algorithm to analyze aCGH data and microarray expression data from 16 low-passage pancreas xenograft samples. Genes which were located near a putative breakpoint and whose expression was altered in a majority of the xenografts samples were considered putative targets. We report here preliminary data concerning one target, Chemokine (CXC motif) Ligand 5 (CXCL5) and its receptor CXCR2/IL8Rb. CXCL5 is a member of the ELR+ Chemokine family, a family of small, secreted ligands which are generally involved in cellular responses to injury and inflammation, but are also implicated in cancer progression and angiogenesis. CXCL5 is up regulated in 12 out of 16 xenograft samples analyzed (75%), with an average fold increase in expression of 41 (range 18 to 59). CXCL5 over-expression was further confirmed by IHC analysis of a custom made primary pancreas tumor microarray. Median IHC score (range 0-3) for CXCL5 in adenocarcinoma epithelial cells is 1.6, versus a median of 0.8 in the matched adjacent normal samples (N=34; p&amp;lt;0.0007 using Mann-Whitney test). Interestingly, the receptor CXCR2 levels are increased in the stroma of tumor samples, with a median IHC score of 1.6 in the stroma surrounding ductal adenocarcinoma versus an IHC score of 0.6 in the stroma of adjacent normal ducts (N=31; p&amp;lt;0.0001 using Mann-Whitney test). These results suggest the stroma surrounding the adenocarcinoma is responding to the over-expression of tumor-derived CXCL5. How CXCL5-induced CXCR2 signaling in the stroma impacts tumor growth and progression is currently being studied using an in-vitro co-culture system with established pancreas epithelial carcinoma cell lines and primary pancreas cancer fibroblasts. Results from these studies will be presented. This work was supported by NIH P01 Grant CA109552. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1338.
Abstract 4346: Differential response of a novel protein kinase C-iota inhibitor (ICA-1) on neuroblastoma cells
Authors: Prajit P. Pillai, Mildred Acevedo-Duncan
Journal: Cancer Research (2011)

Abstract Neuroblastoma is the most common extra cranial tumor diagnosed in children and in infants. The focus of this research was to establish the efficacy of ICA-1 as a novel chemotherapeutic agent for neuroblastoma. ICA-1 was designed to target Protein kinase C-iota (PKC-ι) which has been shown to promote resistance to drug-induced apoptosis in cancer cells, a major obstacle to good prognosis in neuroblastoma. Our preliminary results from in-vitro kinase activity assay demonstrated that ICA-1 selectively downregulated the activity of PKC-ι but had no effect on the activity of PKC-zeta, the closely related family member of the atypical PKC family. Phenotypically, neuroblastoma cells can be divided into 3 distinct groups- sympathoadrenal neuroblasts or N-type that form slow growing tumors, non-neuronal precursor cells or S-type which are non-malignant and I-type which are morphologically and biochemically intermediate to that of N and S cells. ICA-1 inhibited the cell proliferation of LA1-55n (N-type) and BE(2)-C (I-type) neuroblastoma cells. The IC50 was 0.1 µM for both cell lines. Interestingly, ICA-1 had no significant effect on the proliferation of LA1-5s (S-type) non-malignant cells. Furthermore, ICA-1 treatment also induced apoptosis in neuroblastoma cells as shown by TUNNEL assay, Caspase activation and PARP cleavage. Thus, our results provide evidence suggesting that ICA-1 is a promising chemotherapeutic for neuroblastoma with negligible toxicity to normal cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4346. doi:10.1158/1538-7445.AM2011-4346
Tc-99m MDP Uptake Secondary to Soft Tissue Extravasation of Calcium Gluconate in a Newborn Thought to Have Osteomyelitis
Authors: Pilar Orellana, Claudia Velasquez, Luis Meneses, Alberto Urioste, Juan Edardo Carreño, Cristian J Garcíia, Felix Sabroso, Pablo Cruces
Journal: Clinical Nuclear Medicine (2002)

ORELLANA, PILAR M.D.*†; VELASQUEZ, CLAUDIA M.D.†; MENESES, LUIS‡; URIOSTE, ALBERTO M.D.†; CARREÑO, JUAN EDUARDO‡; GARCÍA, CRISTIAN J. M.D.*†; SABROSO, FELIX T.M.*; CRUCES, PABLO M.D.† Author Information
MAJOR COMPLICATIONS ASSOCIATED WITH HEARTMATE II LEFT VENTRICULAR ASSISTED DEVICE: A FOOD AND DRUG ADMINISTRATION MANUFACTURER AND USER DEVICE EXPERIENCE (MAUDE) DATABASE STUDY
Authors: Abel Casso Dominguez, Saurav Chatterjee, Manpreet Singh Sabharwal, Georges El-Hayek, Sunit Chaudhry, Jasjit Bhinder, Pragya Ranjan
Journal: Journal of the American College of Cardiology (2015)
Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Clinically Node Negative Patients after Neoadjuvant Chemotherapy for Breast Cancer – A Systematic Review and Metaanalysis.
Authors: V. Tan, S. Lee, B. Goh, A. Chung, M. Sebastian, W. Yong, W. Wong
Journal: Cancer Research (2009)

Abstract BackgroundThe sentinel lymph node biopsy (SLNB) has become an accepted alternative to the axillary lymph node dissection (ALND) for pathologic evaluation of the axillary lymph node status in patients with early breast cancer and a clinically negative axilla. Patients with a negative sentinel lymph node are spared the ALND and its associated morbidities.Currently, there is insufficient evidence to recommend the use of SLNB in patients who have received neoadjuvant chemotherapy (NAC), and treatment of the axilla after neoadjuvant chemotherapy is an ALND.The use of neoadjuvant chemotherapy is increasing, and NAC has been shown to downstage both the primary tumour and axillary lymph nodes. Potentially, an additional proportion of patients who are node negative after NAC may be spared a full ALND and its attendant morbidities.AimsTo determine the feasibility and accuracy of SLNB in patients who have a clinically negative axilla after neoadjuvant chemotherapy for breast cancer.MethodsA systematic review of the English literature of SLNB in patients who have had neoadjuvant chemotherapy (NAC) was conducted and meta analyses performed. Studies selected had an identifiable group of patients with breast cancer who received neoadjuvant chemotherapy and were clinically node negative. These patients had a SLNB prior to the standard ALND regardless of outcome of the SLNB.ResultsTen studies that met the eligibility criteria were identified. A total of 449 patients were studied. Pooled analysis using the fixed effects model was used to calculate successful identification rate and accuracy parameters. The summary rate of identification of SLN was 94% [95% CI: 91.6% – 96.7%]. The pooled sensitivity of SLNB after NAC was 93% [95% CI: 88.5% – 96.8%] and the false negative rate 7.0% [95% CI: 3.2% – 11.5%].ConclusionSLNB in patients with a clinically node negative axilla after neoadjuvant chemotherapy is feasible and accurate. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 1013.
Subgroup Analyses in RAS Mutant, BRAF Mutant and “ALL WT” Metastatic Colorectal Cancer Patients Treated with Folfoxiri Plus Bevacizumab (BEV) or Folfiri Plus BEV in the Tribe Study
Authors: C. Cremolini, F. Loupakis, S. Lonardi, G. Tomasello, M. Ronzoni, A. Zaniboni, G. Tonini, C. Valsuani, S. Chiara, C. Boni, L. Marcucci, F.V. Negri, C. Barone, S. Vitello, M. D'Amico, C. Granetto, C. Antoniotti, L. Salvatore, G. Fontanini, D. Tomcikova, L. Boni, A. Falcone
Journal: Annals of Oncology (2014)
Neurologic Complications of the Reactivation of Varicella–Zoster Virus
Authors: Donald H. Gilden, B.K. Kleinschmidt-DeMasters, James J. LaGuardia, Ravi Mahalingam, Randall J. Cohrs
Journal: New England Journal of Medicine (2000)

Varicella–zoster virus is an exclusively human herpesvirus that causes chickenpox (varicella), becomes latent in cranial-nerve and dorsal-root ganglia, and frequently reactivates decades later to produce shingles (zoster) and postherpetic neuralgia. In immunocompetent elderly persons or immunocompromised patients, varicella–zoster virus may produce disease of the central nervous system.Since the last major review of varicella–zoster virus in the Journal, 1,2 advances in molecular biology have provided important new insights into the pathogenesis of infection with varicella–zoster virus. The detection of varicella–zoster virus in blood vessels and other tissues by methods based on the polymerase chain reaction (PCR) has widened the recognized . . .
P2-15-03: Nipple-Sparing Mastectomy for Breast Cancer in Japanese Experience: An Assessment from Long Follow-Up Data of Complication and Cancer Control in 806 Patients.
Authors: T Sakurai, T Sakurai, T Umemura, E Jinta, T Suzuma, G Yoshimura
Journal: Cancer Research (2011)

Abstract [Introduction] Mastectomy has been conducted in general for cases in which breast conservation is inapplicable. Since Nipple-sparing Mastectomy (NSM) conserves nipple-areola, it is not only more advantageous in an aspect that nipple-areola reconstruction isn't required in case of breast reconstruction compared with mastectomy but also significantly meaningful because the sensation of nipple-areola is preserved in about 70% cases by skin flap preparation based on thick flap method we have adopted. On the other hand, NSM is controversial relating to complication of surgery and recurrence as well. [Objective] We've made (1) review of safety in NSM surgical technique, (2) discussion over recurrence and prognosis comparing with those in mastectomy, and (3) consideration of performance in immediate reconstructions. [Result] (1) Of all cases of NSM, the number of cases in stage 0, 1, 2A, 2B, 3 and 4 was 21, 305, 239, 123, 112 and 6 respectively. During 104 months of follow-up period in average, total of seven complication cases (0.9%) were observed, including two flap necrosis cases and five postoperative bleeding cases, but no nipple necrosis case was recorded. Although nipple-areola recurrence rate (%) in stage 0, 1, 2A, 2B and 3A was 0, 2.9, 4.6, 2.4 and 5.3 respectively, prognosis of nipple-areola recurrence cases was good showing no difference between stages (OS: 60M; 93%, 100M; 84%). Skin flap recurrence rate (%) in stage 0, 1, 2A, 2B and 3 was 0, 3.2, 3.3, 4.0 and 14.2 respectively, and prognosis of skin flap recurrence cases was significantly worse in stage 2B and 3 compared with that in stage 1 and 2A (p &amp;lt; 0.001). (2) We analyzed local recurrence rate, recurrent free survival and overall survival between 806 of NSM cases and 200 of mastectomy cases which had been performed during the same period, and the result showed no significant difference in those rates between NSM and mastectomy cases. (3) Infectious complication was observed in one out of 18 immediate reconstruction cases using free dermal fat graft. Among 124 immediate reconstruction cases using implant, complications were observed in five postoperative bleeding. [Conclusion] NSM was excellent in cosmetic aspect showing equivalent results in local recurrence rate and prognosis compared with those in mastectomy cases. Besides, patient's satisfaction was also higher in those who had had NSM alone without reconstruction. Our long term follow-up data shows that NSM may be considered as an alternative option for mastectomy in cases in which breast-conserving surgery is inapplicable in breast cancer patients. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-15-03.
AB0297 Dose reduction in patients with rheumatoid arthritis responding to the standard rituximab regimen.
Authors: A. Batticciotto, V. Varisco, M. Antivalle, R. Talotta, F. Rigamonti, D. Ventura, F. Atzeni, P. Sarzi-Puttini
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Rituximab (RTX), a chimeric anti-CD20 monoclonal antibody, safe and effective in rheumatoid arthritis (RA) patients with inadequate response orintolerant to tumor necrosis factor (TNF) inhibitorshas been approved at dose of 1g fortnightlyevery six months. The SERENA and MIRROR studies have shown that response rates are similar in patients treated with 2x0.5g and 2x1g every six months, but there is no agreement concerning the optimal RTX strategy over time (1.2). <h3>Objectives</h3> To verify whether RA patientsEULAR responders after the third course of RTX 2x1g achieve the same result after reducing RTX doseto 2x0.5g <h3>Methods</h3> Among seventy active RA patients with inadequate response to MTX (range 7.5-20 mg/week) and at least one anti-TNF inhibitor treated in our Center since 2007 we selected twenty-one patients that reached a good-moderate EULAR response after treatment with three courses of RTX 2x1g every six months. At the fourth course they were randomly treated with RTX 2x0.5g (group 1: 10 patients, 9 F, mean age 48 years, range 21-68; mean disease duration 9.7±6.2 years, 5 RF + and 6 anti-CCP +, baseline DAS28: 4.62±0.98) or RTX 2x1g (group 2: 11 patients, 8 F, mean age 61 years, range 39-74; mean disease duration 11.1 ± 8.3 years, 9 RF + and 8 anti-CCP +, baseline DAS28: 4.85±1.35) every six months for 52 weeks <h3>Results</h3> No difference between the two groups in disease duration (p=0.832), baseline DAS28 (p=0.647), percentage of patient RF+ (p=0.055) and anti-CCP+ (p=0.126) are observed. The percentage of patients in low disease activity (LDA) or remission based on DAS28 were similar in both groups after the fourth (70.0% <i>vs</i> 72.8% p=1,0) and fifth course (83.3% <i>vs</i> 66.7% p= 0.545). They maintained the same rate of EULAR response respect baseline (100% <i>vs</i> 90.1% p= 1 after course four and 100% <i>vs</i> 100% after course five). <h3>Conclusions</h3> In patients responders to three standard doses of RTX, it is possible to reduce the dose to 2x0,5g without affecting response and optimizing the pharmacoeconomic impact. Further studies to evaluate the radiological progression of RA after dose reduction are suggested. <h3>References</h3> Emery P, <i>et al.</i> Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (SERENE). Ann Rheum Dis. 2010;69:1629-35. Rubbert-Roth A, <i>et al</i>. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (<i>Oxford</i>). 2010;49:1683-93. <h3>Disclosure of Interest</h3> None Declared